Form 4: Cartesian Therapeutics Executive Sells Shares After Option Exercise

A Cartesian Therapeutics executive, Metin Kurtoglu, exercised stock options and sold shares in multiple transactions over two days.

Summary

• Metin Kurtoglu, Chief Technology Officer of Cartesian Therapeutics, exercised stock options to acquire common stock.
• He then sold a portion of these shares in multiple transactions on December 9th and 10th, 2024.
• On December 9th, 10,763 shares were acquired at $1.41 each and 10,763 options were exercised.
• On December 9th, 6,224 shares were sold at a weighted average price of $25.2629, with prices ranging from $24.58 to $25.57.
• Also on December 9th, 4,539 shares were sold at a weighted average price of $25.8333, with prices ranging from $25.58 to $26.14.
• On December 10th, 2,901 shares were acquired at $1.41 each and 2,901 options were exercised.
• On December 10th, 2,901 shares were sold at a weighted average price of $24.3503, with prices ranging from $24.00 to $24.78.
• The options were fully vested and exercisable following the merger on November 13, 2023.
• Options to purchase Old Cartesian common stock were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger.
• On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

Sentiment

Score: 5

Explanation: The document is neutral, detailing standard executive stock transactions. There is no indication of positive or negative sentiment, just factual reporting.

Positives

• The executive exercised options, indicating confidence in the company's future.
• The sales of shares were at prices significantly higher than the exercise price of $1.41.

Negatives

• The executive sold a significant portion of the shares acquired through option exercises.

Risks

• Executive share sales could be interpreted negatively by the market.
• The weighted average sale prices varied slightly across the transactions.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and this filing provides transparency into the actions of a key executive at Cartesian Therapeutics.

Comparison to Industry Standards

• Executive stock option exercises and subsequent sales are a standard practice across the biotechnology industry.
• The reported weighted average sale prices are within the typical range for such transactions, reflecting market conditions at the time of the sales.
• Comparable companies often see similar patterns of executive stock transactions, especially after significant corporate events like mergers.

Stakeholder Impact

• Shareholders may interpret the executive's share sales as a lack of confidence, although this is a common practice after option exercises.
• The transactions have no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Cartesian Therapeutics, stock options, share sales, executive transactions, insider trading, Metin Kurtoglu, RNAC